ANEMIA OF CHRONIC DISORDERS
pathologist [4] . His hospital laboratory possessed samples of plasma from a great variety of patients with different illnesses. Locke et al found that specimens from "The use of iron pills as a 'tonic' or for the treatment persons undergoing inflammatory defense processes are of an undiagnosed anemia can never be condoned" [1] .
hypoferremic. If patients recovered, normal levels of iron Anemia is a common finding in cancer patients. The would return. Other research workers subsequently condition has no dearth of etiologic factors [2] . Hemoglodemonstrated that this profound shift in iron metabolism is independent of dietary iron, regulated by cytokines, bin (Hb) synthesis may be impaired by nutritional defiand is important for host defense. ciencies (iron, folic acid, cobalamin). Erythrocyte syntheIn addition to its occurrence in neoplastic and infecsis may be depressed by bone marrow inadequacy tious diseases, ACD is seen in patients with such other (metastases, pure red cell aplasia, chemotherapy, or racauses of inflammation as rheumatoid arthritis, systemic diotherapy) or, in renal failure, by erythropoietin (EPO) lupus erythematosis, and inflammatory bowel disease, as deficiency. Erythrocyte quantity may be reduced by well as in persons who recently have had major trauma bleeding, hemolysis, or hypersplenism. Frequently, the or surgery. Examples of chronic disorders in which ACD anemia ensues from attempts of the host to raise an typically does not occur include diabetes mellitus, hyperinflammatory response to defeat the neoplastic invader.
tension, asthma, ischemic heart disease, and congestive This condition has been termed the "anemia of chronic heart failure. disorders" (ACD) or, more recently, the "hypoferremia Together with the hypoferremia, features of ACD inof inflammatory diseases."
clude lowered values of transferrin iron saturation and Manifestly, the selection of methods for correction of transferrin iron-binding capacity, high normal or eleanemia in cancer patients requires precise knowledge of vated serum ferritin, and ample marrow deposits. Intestiits cause. For some etiologies, exogenous iron is indinal assimilation of iron is depressed [5] ; nevertheless, cated; for others, feeding or injecting iron would be futile serum transferrin iron receptor concentration remains or even counterproductive. Clearly, if the particular anenormal [6] . This constellation of traits indicates that mia is caused or complicated by iron deficiency, therapy plasma iron is being lowered by a reduction in the recyshould include replenishment of the metal. However, cling of iron to plasma from macrophages that have diexcessive amounts of exogenous iron can enhance prolifgested Hb from effete erythrocytes, as well as by an eration of cancer cells and depress cell-mediated immuelevation of the mucosal block that controls assimilation nity [3] . Accordingly, all patients who are being treated of dietary iron. with the metal, irrespective of the cause(s) of their aneIn normal adults, serum ferritin values are 20 to 200 ng/ml; if below 15 ng/ml, iron deficiency is present. During ACD, additional ferritin is formed to aid in the up-
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50 ng/ml [1] . Serum ferritin values of greater than 300 anemia usually is normocytic and normochromic, mild microcytosis and hypochromia may occur. Hematocrits ng/ml in persons with or without ACD indicate that the tissues contain excessive amounts of iron deposits.
range from 20% to 40%. In ACD, the erythrocyte life span can be moderately shortened, but the primary cause Ferritin molecules that appear in serum during inflammation contain less iron than normal [7] , presumably of the anemia is the failure of the bone marrow to increase the number of circulating reticulocytes. because they have recently been synthesized. Moreover, some of the elevated serum ferritin in cancer patients Serum EPO levels in patients with ACD, although higher than normal, are lower than in patients with anemay result from production of the protein by tumor cells [8] . Note also that when ferritin is secreted by intact mia from noninflammatory disorders and are lower than expected for the degree of anemia. However, the marrow cells, it is glycosylated; when it leaks from damaged cells, responds to exogenous EPO. For example, a set of 10 it is nonglycosylated [9] .
rheumatoid arthritis patients with ACD were treated for 32 weeks with EPO plus oral iron, and their hematocrits IRON-WITHHOLDING DEFENSE SYSTEM increased from an initial mean of 31% to a final mean The consistently observed shift in iron metabolism in of 40.8% [14] . Likewise, in 17 patients with inflammatory ACD is but one aspect of the extensive iron-withholding bowel disease who had chronic anemia, administration defense system [10] . Additional features of the system of EPO plus oral iron for 12 weeks resulted in a mean include the continuous presence of: (a) moderately unHb concentration that increased from an initial value of saturated transferrin in plasma, lymphatic fluid, and cere-8.81 Ϯ 0.27 g/dl to a final value of 10.52 Ϯ 0.41 g/dl [15] . brospinal fluid; (b) unsaturated (apo) lactoferrin in tears,
In these studies, hematocrits and Hb values remained milk, secretions of respiratory, gastrointestinal, and genilow in patients who received oral iron without EPO. tal tracts, and in secondary granules of neutrophils; and In a study of 17 patients with colorectal cancer, EPO (c) ferritin in all body cells. Furthermore, when iron was given from 10 days prior to two days after surgery withholding is up-regulated, neutrophils discharge apo- [16] . Favorable response was correlated positively with lactoferrin into sites of inflammation. Macrophages scavserum ferritin values (P Ͻ 0.001) and with transferrin enge lactoferrin-acquired iron; haptoglobin and hemoiron saturation (P ϭ 0.0004). When transferrin iron satupexin bind extravasated Hb and hemin, and nitric oxide ration was 15% or less, hypochromic erythrocytes were effects efflux of nonheme iron from tumor and other formed. The ability of EPO to stimulate production of targeted cells. These and other features of the iron-witherythrocytes normal both in size and Hb content is highly holding defense system are essential in suppressing the dependent on availability of functional iron [17] . proliferative action of iron for neoplastic and microbial
In conditions in which the anemia results from both cell invaders, as well as in preventing the hazardous bleeding and ACD, intravenous (i.v.) iron without EPO oxidant action of the metal toward normal cells and may be effective. In a recent study, 40 patients with tissues.
Crohn's disease (Hb Յ 10.5 g/dl) were given a total of In the inflammatory response to insult, iron-withhold-3.5 g i.v. iron over 16 weeks [18] . In the first eight weeks, ing defense is intensified by increased production of such half were given EPO, half placebo. In the second eightcytokines as interleukin-1 and interleukin-6, tumor neweek period, EPO was increased or initiated for the crosis factor-␣ (TNF-␣), and interferon-␥. Interleukin-1 nonresponders in each group. Seventy-five percent of and interluekin-6 and TNF-␣, formed by activated macthe patients had a substantial response to i.v. iron alone. rophages and other cells, can induce suppression of intes-EPO plus i.v. iron permitted a somewhat more rapid tinal iron assimilation, reduction in recycling of iron from increase in Hb concentration as well as a lesser tendency macrophages to plasma, and increased synthesis of ferrito develop excessive transferrin iron saturation values tin to sequester macrophage-retained iron [5, 11] . Interas compared with i.v. iron alone. However, the authors feron-␥, produced by T-lymphocytes, induces macronoted that i.v. iron alone was more effective than EPO phages to form nitric oxide, which causes depletion of plus oral iron in improving Hb values in Crohn's disease nonheme iron in tumor and other targeted cells [12] . patients. They recommended that i.v. iron saccharate, in Inhibitory activities of nitric oxide are reversed by exogewhich the cost is only 0.8% that of EPO, be considered nous iron [13] . first-line therapy in patients with severe anemia.
HAZARDS OF IRON LOADING THERAPEUTIC USE OF EPO AND IRON
A mild to moderate anemia (so-called ACD) freUnfortunately, unless the patient's condition involves bleeding, large amounts of injected iron (either as requently accompanies inflammatory illnesses. In chronic conditions, the anemia develops during the first few peated quantities of 0.2 g/dose of iron as saccharate or repeated transfusions of 0.2 g of iron per unit of whole months and rarely progresses thereafter. Although the
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blood) cannot be given without serious long-term conseof 41,276 men and women followed for 14 years, 6% quences. In the study mentioned earlier [18] , i.v. iron developed cancers. Among persons in the group whose was halted when the transferrin iron saturation value initial transferrin iron saturation value was more than exceeded 50%. In such patients, the value returned to 60%, the relative risk (as compared with those with levels normal within two weeks. However, it was not deterof less than 60%) for all cancers, lung cancer, and colomined how much of the excess iron had been excreted rectal cancer was 1.43, 1.51, and 3.04, respectively [25] . in bleeding or how much had been deposited in such As indicated earlier here, blood transfusions can result vulnerable tissues as heart, liver, endocrine glands, or in iron loading. A meta-analysis of 60 studies comprising joints. It has long been known that parenteral administra-19,687 patients (1982 to 1994) of perioperative blood tion of iron during episodes of inflammation does not transfusions and cancer recurrence found an adverse efrestore the normal level of plasma iron; instead, the fect in 28 of the reports with an increased risk of 37% metal is deposited in the monocyte/macrophage system [26] . As a corollary, in a study of 37,795 normal blood [19, 20] . As this system becomes saturated with iron, the donors, the relative risk of developing cancers as commetal overflows into hazardous tissue sites. pared with nondonors was 0.79 (P Ͻ 0.001) [27] . The total amount of iron in a normal adult should not Iron loading can occur not only via alimentary and exceed 4 to 5 g. By the time that the quantity of iron in parenteral routes but also by inhalation of the metal a human has increased to 15 g, sufficient organ deterioracontained in tobacco smoke, asbestos, and urban air partion has occurred to require medical assistance [21] . The ticulates [3, 28] . Moreover, iron can be released from its metal contributes to a considerable panoply of diseases normal body compartments by hemolysis or by destructhat varies with individual patients. The association of tion of nonerythrocytic cells that contain iron deposits. iron loading with initiation and proliferation of neoFor example, endogenous iron released from dying cells plasms is well established [3] . Iron is carcinogenic bein 40 patients given high doses of cytostatic drugs and cause of its catalytic effect on the formation of hydroxyl total body irradiation (two weeks prior to bone marrow radicals, suppression of the activity of host defense cells, transplantation) resulted in transferrin iron saturation and promotion of cancer cell multiplication. In both animal models and in humans, primary neoplasms develop values of 75% to 100% [29] . at tissue sites of excessive iron deposition.
Patients with ACD who might be considered for therDuring the past four decades, numerous research apy with EPO plus iron are those with Hb of less than groups have reported, in prospective studies in animals, 10.5 g/dl, hypochromic red blood cells of more than 10%, that administration of excessive amounts of injected or and serum EPO of less than 200 mU/ml. Sufficient EPO oral iron increases markedly the risk of adenocarcinoplus iron should be given to maintain transferrin iron mas, colorectal tumors, hepatomas, mammary tumors, saturation values of 25% to 35% and hematocrit values mesotheliomas, renal tubular cell carcinomas, and sarcoof 30% to 36%. The amount of EPO required to amemas [3] . In humans, these types of prospective studies liorate anemia in ACD is threefold higher than that would be unethical. However, in large groups of humans needed in patients who have chronic renal failure withsuch as 0.5% of whites [22] and 10% of sub-Saharan out ACD [2] . Africans [23] , genetic defects result in assimilation of If oral iron is employed, note that in ACD, intestinal excessive dietary iron. In the white disease, hereditary assimilation of the metal is dampened. If i.v. iron is hemochromatosis, the elevation in tissue iron is associused, the intervals at which transferrin iron saturation ated with an increase in hepatic carcinoma of as much is monitored should be shortened. Moreover, if cancer as 200-fold; excessive frequency of nonhepatic malignanpatients are being treated with experimental protocols cies also is observed [3, 22] . In the African disease, Afrithat contain such inhibitors of cancer cell iron metabocan siderosis, the incidence of hepatic carcinoma likewise lism as gallium, iron chelators, or antibodies to transis quite high. For example, in one study of persons with ferrin receptors, additional care to avoid iron overload elevated tissue iron, an increased cancer risk of 15-fold must be exercised. was observed [23] .
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had a mean transferrin iron saturation value of 33.1% at least four years prior to diagnosis, whereas the men 
